NHS Bath and North East Somerset, Swindon and Wiltshire CCG Royal United Hospitals Bath NHS Foundation Trust Great Western Hospitals NHS Foundation Trust Salisbury NHS Foundation Trust
Tablets 2.5mg/5mg and orodispersible tablets 2.5mg/5mg
Nasal spray 5mg/0.1ml actuation
Also used for menstrual migraine 2.5mg twice to three times a day on days when migraine expected (off-label).
Frovatriptan (Oral)
Formulary
2.5mg tablets
Current evidence base supports the use of Frovatriptan as a first-line acute treatment for Menstrual Migraine and for perimenstrual prophylaxis. No triptan is specifically licensed for this indication (off-label).
For the treatment of menstrual migraine only when other triptans (sumatriptan / zolmitriptan) have proven ineffective. Give 2.5mg twice daily on days when migraine expected.
Frovatriptan is distinctive from other triptans due to its long elimination half-life of 26 hours, which confers a longer duration of action.
04.07.04.01
Ergot alkaloids
04.07.04.01
Anti-emetics
04.07.04.01
Other drugs for migrane
....
Non Formulary Items
Eletriptan
(Relpax®)
Non Formulary
Naratriptan
(Naramig®)
Non Formulary
Rizatriptan
(Maxalt®)
Non Formulary
Sumatriptan
(Imigran® Radis)
Non Formulary
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
High Cost Drug Approval System
Traffic Light Status Information
Status
Description
RED - Hospital only – to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.
Amber medicines are considered suitable for GP prescribing following specialist initiation or recommendation.
Shared Care - these medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place status reverts to red.
These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations.
Suitable for patient to be directed to buy themselves
Not currently used. We intend to include this TLS in future to highlight where a decision to use this medicine is under review.
(In use from Oct 2020) Used where a decision has been made by the BSW APC not to routinely commission this preparation for its licensed indications. Do not prescribe.
Not currently used. We intend to include this TLS in future to highlight where this medicine and indication is ONLY available through a Specialist Centre according to a NICE Highly Specialised Technology or NHSE Specialised Commission Circular / Policy.
